LONDON — When Europe’s largest cardiology conference opened here this past Friday, one of the first sessions centered entirely on a single drug.
It cut the risk of complications from a common form of heart failure, researchers reported. It helped improve the structure of the heart as well as its function. It even saved the lives of people with Covid-19 — a respiratory infection of all things.
“Now on to something entirely different,” Richard Pratley, a diabetes specialist at AdventHealth in Orlando, told the standing-room-only crowd as he introduced a trial of the drug in kidney disease.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
View All Plans
_posing_on_a_leaf-Ger_Bosma_Photos_cc529fd2cce94bb2a9f117448048c0d1-620x480.jpg?w=350&resize=350,250&ssl=1 "Fruit flies steal bacterial defense to survive parasitic wasps")
_posing_on_a_leaf-Ger_Bosma_Photos_cc529fd2cce94bb2a9f117448048c0d1-620x480.jpg?w=120&resize=120,86&ssl=1 "Fruit flies steal bacterial defense to survive parasitic wasps")
